Leerink Swann Lowers Estimate for Illumina's Q1 Revenues, EPS

The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories